Evidence map›Paper›PMID 36110429›Full record

ArticleFrontiers in aging neuroscience2022

Alzheimer's Disease Polygenic Risk Score Is Not Associated With Cognitive Decline Among Older Adults With Type 2 Diabetes.

Sigalit B Manzali, Eric Yu, Ramit Ravona-Springer, Abigail Livny, Sapir Golan, Yuxia Ouyang, Orit Lesman-Segev, Lang Liu, Ithamar Ganmore, Anna Alkelai and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Sigalit B ManzaliDepartment of Pathology, Sheba Medical Center, Tel Hashomer, Israel.
Eric YuDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Ramit Ravona-SpringerThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Abigail LivnyThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Sapir GolanThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Yuxia OuyangDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Orit Lesman-SegevThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Lang LiuDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Ithamar GanmoreThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Anna AlkelaiInstitute for Genomic Medicine, Columbia University Medical Center, New York, NY, United States.
Ziv Gan-OrDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Hung-Mo LinDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Anthony HeymannSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Michal Schnaider BeeriThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Lior GreenbaumThe Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Sheba Medical Center · ILIcahn School of Medicine at Mount Sinai · USTel Aviv University · ILMontreal Neurological Institute and Hospital · CAColumbia University Irving Medical Center · USMcGill University · CA

Funding

Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular diseaseR01AG061093 · NIA · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI SCHNAIDER BEERI, MICHAL · 2019 to 2024
$4.3M
NIA NIH HHS R01 AG061093
6 · The paper itself

Abstract

Objectives: Multiple risk loci for late-onset Alzheimer's disease (LOAD) have been identified. Type 2 diabetes (T2D) is a risk factor for cognitive decline, dementia and Alzheimer's disease (AD). We investigated the association of polygenic risk score (PRS) for LOAD with overall cognitive functioning and longitudinal decline, among older adults with T2D. Methods: The study included 1046 Jewish participants from the Israel Diabetes and Cognitive Decline (IDCD) study, aged ≥ 65 years, diagnosed with T2D, and cognitively normal at baseline. The PRS included variants from 26 LOAD associated loci (at genome-wide significance level), and was calculated with and without Results: The PRS was not significantly associated with overall functioning or decline in global cognition or any of the specific cognitive domains. Similarly, following correction for multiple testing, there was no association with Aβ burden and other brain imaging phenotypes. Conclusion: Our results suggest that the cumulative effect of LOAD susceptibility loci is not associated with a greater rate of cognitive decline in older adults with T2D, and other pathways may underlie this link.

Indexed as

agingAlzheimer’s diseasecognitive declinepolygenic risk scoretype 2 diabetes

Identifiers

PMID36110429
PMCPMC9468264
OpenAlexW4293770207

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.